Evidence map›Paper›PMID 25363021›Full record

ArticleBMC cancer2014

Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein.

Heidi Schwarzenbach, Corinna Eichelser, Bettina Steinbach, Josefine Tadewaldt, Klaus Pantel, Victor Lobanenkov, Dmitri Loukinov

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Pathogenicity of the MAGE family.Oncology letters · 2021
    Review
  4. Review
  5. BORIS: a key regulator of cancer stemness.Cancer cell international · 2018
    Review
  6. The MAGE protein family and cancer.Current opinion in cell biology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Heidi SchwarzenbachDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg 20246, Germany. hschwarz@uke.uni-hamburg.de.
Corinna Eichelser
Bettina Steinbach
Josefine Tadewaldt
Klaus Pantel
Victor Lobanenkov
Dmitri Loukinov
University Medical Center Hamburg-Eppendorf · DENational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · US

Funding

Regulation of CTCF Functions and Target Sites by Cancer/Testis-specific CTCF Like BORIS FactorZIAAI001021 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LOBANENKOV, VICTOR · 2009 to 2025
$12.7M
6 · The paper itself

Abstract

backgroundAs cancer-testis MAGE-A antigens are targets for tumor immunotherapy, it is important to study the regulation of their expression in cancers. This regulation appears to be rather complex and at the moment controversial. Although it is generally accepted that MAGE-A expression is controlled by epigenetics, the exact mechanisms of that control remain poorly understood.

methodsWe analyzed the interplay of another cancer-testis gene, BORIS, and the transcription factors Ets-1 and Sp1 in the regulation of MAGE-A1 gene expression performing luciferase assays, quantitative real-time PCR, sodium bisulfite sequencing, chromatin immunoprecipitation assays and pull down experiments.

resultsWe detected that ectopically expressed BORIS could activate and demethylate both endogenous and methylated reporter MAGE-A1 promoter in MCF-7 and micrometastatic BCM1 cancer cell lines. Overexpression of Ets-1 could not further upregulate the promoter activity mediated by BORIS. Surprisingly, in co-transfection experiments we observed that Sp1 partly repressed the BORIS-mediated stimulation, while addition of Ets-1 expression plasmid abrogated the Sp1 mediated repression of MAGE-A1 promoter. Both BORIS and Sp1 interacted with the TATA binding protein (hTBP) suggesting the possibility of a competitive mechanism of action between BORIS and Sp1.

conclusionsOur findings show that BORIS and Sp1 have opposite effects on the regulation of MAGE-A1 gene expression. This differential regulation may be explained by direct protein-protein interaction of both factors or by interaction of MAGE-A1 promoter with BORIS alternatively spliced isoforms with different sequence specificity. We also show here that ectopic expression of BORIS can activate transcription from its own locus, inducing all its splice variants.

Indexed as

Gene Expression Regulation, NeoplasticPromoter Regions, GeneticAlternative SplicingCell Line, TumorDNA-Binding ProteinsDNA MethylationGene Knockdown TechniquesGenetic LociHistonesHumansMCF-7 CellsNeoplasm ProteinsPeptide FragmentsProtein BindingProto-Oncogene Protein c-ets-1RNA InterferenceCTCFL protein, humanDNA-Binding ProteinsHistonesMAGE-A1 protein (278-286), humanNeoplasm ProteinsPeptide FragmentsProto-Oncogene Protein c-ets-1RNA, MessengerRNA, Small InterferingSp1 Transcription FactorTATA-Box Binding Protein

Identifiers

PMID25363021
PMCPMC4230356
OpenAlexW2029705762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.